Actively Recruiting

Age: 18Years +
All Genders
NCT04587388

Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry

Led by European Hematology Association - Lymphoma Group · Updated on 2020-10-14

500

Participants Needed

11

Research Sites

365 weeks

Total Duration

On this page

Sponsors

E

European Hematology Association - Lymphoma Group

Lead Sponsor

A

Associazione Angela Serra per la ricerca sul cancro

Collaborating Sponsor

AI-Summary

What this Trial Is About

The optimal treatment strategy in patients with early progressive disease is not well known. In recent years, novel insights into the biology of Follicular Lymphoma (FL), and especially the role of the microenvironment, have resulted in the development of multiple novel treatment modalities. These new agents may ultimately improve the outlook for patients with FL with an unfavorable course, but for the development of the optimal therapeutic strategy, knowledge on the clinical and biological determinants of early refractory FL is needed.

CONDITIONS

Official Title

Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with initial diagnosis of follicular lymphoma, refractory/relapsed/transformed after first line therapy
  • All stages at the time of relapse
  • Histological grade 1-3a at the time of initial diagnosis
  • Age over 18 years
  • Availability of clinical data, including baseline information, comorbidities, data on disease localization, laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating as requested
  • Diagnostic material available for review
  • Written informed consent
Not Eligible

You will not qualify if you...

  • Age < 18 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 11 locations

1

Klinički Bolnički Centar Split

Split, Croatia, 21000

Actively Recruiting

2

AOU Città della Salute e della Scienza di Torino

Torino, Italy, 10126

Actively Recruiting

3

Academic Medical Center

Amsterdam, Netherlands, 1105 AZ

Actively Recruiting

4

University Medical Center Groningen

Groningen, Netherlands, 9713 GZ

Actively Recruiting

5

Instituto Português de Oncologia Francisco Gentil

Lisbon, Portugal

Actively Recruiting

6

Hospital Clinic de Barcelona

Barcelona, Spain, 08036

Actively Recruiting

7

Hospital 12 de Octubre

Madrid, Spain, 28041

Actively Recruiting

8

Hospital Jose Maria Morales Meseguer

Murcia, Spain, 30008

Actively Recruiting

9

Hospital de Son Llàtzer

Palma, Spain, 07198

Actively Recruiting

10

Hospital Universitario de Salamanca

Salamanca, Spain, 37007

Actively Recruiting

11

Kiev National Cancer Institute

Kiev, Ukraine, 03022

Actively Recruiting

Loading map...

Research Team

S

Sanne Tonino, MD

CONTACT

I

Irene Dogliotti, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry | DecenTrialz